Tovorafenib Alternatives Compared
Tovorafenib | Mekinist (trametinib) | Tafinlar (dabrafenib) |
|
---|
Tovorafenib | Mekinist (trametinib) | Tafinlar (dabrafenib) |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Low-Grade Glioma. Tovorafenib may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Thyroid Cancer, Low-Grade Glioma, Melanoma - Metastatic, Solid Tumors, Non Small Cell Lung Cancer. Mekinist may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Melanoma - Metastatic, Thyroid Cancer, Low-Grade Glioma, Non Small Cell Lung Cancer, Solid Tumors. Tafinlar may also be used for purposes not listed in this medication guide. |
Related suggestions Low-Grade Glioma
|
|||||||||||||||
More about Tovorafenib | More about Mekinist (trametinib) | More about Tafinlar (dabrafenib) | ||||||||||||||||
Ratings & Reviews | ||||||||||||||||||
Be the first to share your experience with this drug. |
Mekinist has an average rating of 7.3 out of 10 from a total of 3 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 33% reported a negative effect. |
Tafinlar has an average rating of 7.5 out of 10 from a total of 2 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
View all Tovorafenib side effects |
View all Mekinist side effects |
View all Tafinlar side effects |
||||||||||||||||
Drug Class | ||||||||||||||||||
Generic Availability | ||||||||||||||||||
N/A |
||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Mekinist prices |
View all Tafinlar prices |
||||||||||||||||
Dosage Forms | ||||||||||||||||||
N/A |
|
|
||||||||||||||||
Brand Names | ||||||||||||||||||
Ojemda |
N/A |
N/A |
||||||||||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
56 hours |
115.2 hours |
22 hours |
||||||||||||||||
CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | ||||||||||||||||||
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | ||||||||||||||||||
A total of 399 drugs are known to interact with Tovorafenib:
|
A total of 33 drugs are known to interact with Mekinist:
|
A total of 505 drugs are known to interact with Tafinlar:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
|
||||||||||||||||
Disease Interactions | ||||||||||||||||||
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||
First Approval Date | ||||||||||||||||||
April 23, 2024 |
May 29, 2013 |
May 29, 2013 |
||||||||||||||||
WADA Class View classifications | ||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||
More Information | ||||||||||||||||||
Patient Resources | ||||||||||||||||||
Professional Resources | ||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.